Latest From Reapplix APS
Following the presentation of results from a randomized trial, Reapplix is ramping up its commercial operations with the hire of a new US president to lead sales of its wound-healing platform, LeucoPatch.
Reapplix, an emerging autologous cell-based wound therapy specialist, has secured additional funding that will take the company through the next year before it gets “market-ready” to launch its diabetic foot ulcer treatment in the US and EU.
Mega-deals and innovative technologies have transformed advanced wound care into a robust, high-tech market in the US. While regulatory and reimbursement challenges persist, opportunities in adjacent spaces and under-penetrated OUS markets represent fertile ground for advanced wound care expansion.
With worldwide revenues projected to reach $6 billion in 2015, mega-deals and innovative game-changing technologies have transformed the advanced wound care market into a robust, high-tech arena in the US. While regulatory and reimbursement challenges persist, opportunities in adjacent spaces and under-penetrated OUS markets represent fertile ground for advanced wound care expansion.
- Gene Therapy, Cell Therapy
- Medical Devices
- Therapeutic Areas
- Wound Healing & Tissue Repair
- Western Europe
- Parent & Subsidiaries
- Reapplix APS
- Senior Management
Niels E Holm, PhD, CEO
Rasmus Lundquist, CSO
- Contact Info
Phone: 88 16 80 66
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.